OSI Pharmaceuticals Announces Conversion Period for Convertible Notes MELVILLE, N.Y.-- (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc.(Nasdaq: OSIP) announced today that its 2% Convertible Senior Notes due 2025 (the notes) are now convertible at the option of the holders and will remain convertible through...
Circulating tumor cells can reveal genetic signature of dangerous lung cancers Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing...
Circulating Tumor Cells Can Reveal Genetic Signature Of Dangerous Lung Cancers A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.'The CTC-chip opens up a whole new field of studying tumors in real time,' says Daniel Haber,...
Promising New Tool to Monitor Lung Cancer Treatment Progress Researchers at Massachusetts General Hospital (MGH) are testing a non-surgical technique that may help doctors monitor how well patients are responding to treatment.Using a device known as a CTC-chip to analyze circulating tumor cells...
OSI Pharmaceuticals Announces Conversion Period for Convertible Notes OSI Pharmaceuticals, Inc.(OSIP) announced today that its 2% Convertible Senior Notes due 2025 (the notes) are now convertible at the option of the holders and will remain convertible through September 30, 2008, the last trading day of the...
Circulating tumor cells can reveal genetic signature of dangerous lung cancers Medicine & Health/ Cancer Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic...
Microchip-based device determines the genetic signature of lung tumors Massachusetts General Hospital (MGH)investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing...
Premium Company Profile - OSI Pharmaceuticals - New Research Report on Companies and Markets Company-Profile/Premium-Comp ..Introduction OSI Pharmaceuticals (OSI Pharma) main focus is to discover and develop novel drugs and build innovative commercialized molecular targeted therapies.
The company has three marketed products,...
Cyclacel to Present at Collins Stewart Fourth Annual Growth Conference BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc.(NASDAQ: CYCC - News), (NASDAQ: CYCCP - News) announced today that John Womelsdorf, Ph.D., Vice President, Business Development, will present an overview of the...
Circulating tumor cells can reveal genetic signature of dangerous lung cancers , 6:05 PM EST (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of...
Genentech Inc (NYSE:DNA) to Release Q2 2008 Earnings July 14 Genentech, Inc.(NYSE:DNA) will release the second quarter earnings for 2008 on Monday, July 14.
A live webcast with Genentech management will follow the release of the financial results at 1:45 pm PT.
To access the webcast, visit the...
Cancer treatment Cancer cases have disturbingly increased in the recent times.An estimated 100,000 new cases of cancer are reported every year.
The exact number of cases may be much higher than this figure as many cases remain undetected or unreported...
A New Citeline Analysis Provides Valuable Clues To Health Of Drug Companies In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing clinical trials activity, and find that...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in the July issue of GCPj, Tracy DeGregorio and Christine Blazynski examine the robustness of the leading pharma and biotech pipelines with respect to ongoing...
A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies In a detailed ranking of companies by ongoing trial activity across six therapeutic areas (autoimmune/inflammation, cardiovascular, CNS, metabolic, infectious diseases, and oncology), this analysis finds that those companies spending in...
OSI shares rise after Thomas Weisel initiates 'Overweight' rating, citing Tarceva sales OSI shares rise after Thomas Weisel initiates 'Overweight' rating, citing Tarceva sales NEW YORK (AP) - Shares of OSI Pharmaceuticals Inc.rose Friday after a Thomas Weisel Partners analysts initiated coverage of the...
OSI shares rise on Weisel 'Overweight' rating Shares of OSI Pharmaceuticals Inc.rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an 'Overweight' rating, citing accelerating sales of the cancer drug Tarceva.
...
OSI shares rise on Weisel 'Overweight' rating NEW YORK - Shares of OSI Pharmaceuticals Inc.rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an 'Overweight' rating, citing accelerating sales of the cancer drug Tarceva. ...
OSI shares rise on Weisel 'Overweight' rating Tarceva, which is approved to treat non-small cell lung cancer and pancreatic cancer and was developed by OSI, is sold by Genentech Inc.Analyst Stephen Willey said Tarceva sales could get a boost from data expected in the...
OSI studying obesity treatment AM Jun.20--OSI Pharmaceuticals Inc., the Melville-based company best known for its work developing an anti-cancer drug, said yesterday it plans to study ways to treat obesity, a growing health problem worldwide and particularly among...
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602 Author : NY-OSI-PHARMACEUTICALS Category : Press Release News Alerts by Email click here ) News | Home MELVILLE, N.Y.- (Business Wire) OSI Pharmaceuticals, Inc.
(Nasdaq: OSIP) announced today that it has initiated the first-in-human...
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602 -OSI Pharmaceuticals, Inc.(Nasdaq: OSIP) announced today that it has initiated the first-in-human clinical study of its development compound PSN602.
Discovered by OSI's diabetes and obesity team, PSN602 is an oral dual serotonin and...
